10x Genomics CEO Serge Saxonov sells 25,000 shares

The sales were made under a Rule 10b5-1 trading plan adopted November 29, 2025.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) Chief Executive Officer Serge Saxonov reported five direct sales totaling 25,000 Class A common shares on September 22, 2026. The reported weighted-average sale prices were $78.2284 for 1,000 shares, $79.6195 for 2,000, $80.9033 for 9,300, $81.8254 for 9,900, and $82.3650 for 2,800 shares. The sales were made under a Rule 10b5-1 trading plan adopted November 29, 2025.

Insider Trade Summary 10b5-1

Net Seller: 25,000 shares

Net Sell 8 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 25,000 shs ($2.03M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	1,000	$78.2284	$78K
Sale	Class A Common Stock F1, F3	2,000	$79.6195	$159K
Sale	Class A Common Stock F1, F4	9,300	$80.9033	$752K
Sale	Class A Common Stock F1, F5	9,900	$81.8254	$810K
Sale	Class A Common Stock F1, F6	2,800	$82.365	$231K
holding	Class A Common Stock F7	--	--	--
holding	Class A Common Stock F8	--	--	--
holding	Class A Common Stock F9	--	--	--

Holdings After Transaction: Class A Common Stock — 1,050,249 shares (Direct); Class A Common Stock — 284,921 shares (Indirect, See footnote)

Footnotes (9)

1. F1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. F5. This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. F6. This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
7. F7. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
8. F8. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
9. F9. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Key Figures

Direct sale: 1,000 shares at weighted average $78.2284 per share Direct sale: 2,000 shares at weighted average $79.6195 per share Direct sale: 9,300 shares at weighted average $80.9033 per share +2 more

5 metrics

Direct sale 1,000 shares at weighted average $78.2284 per share September 22, 2026

Direct sale 2,000 shares at weighted average $79.6195 per share September 22, 2026

Direct sale 9,300 shares at weighted average $80.9033 per share September 22, 2026

Direct sale 9,900 shares at weighted average $81.8254 per share September 22, 2026

Direct sale 2,800 shares at weighted average $82.3650 per share September 22, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, trustee

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"reflects the weighted average sale price"

trustee regulatory

"for which the Reporting Person serves as trustee"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TXG shares did CEO Serge Saxonov sell, and at what prices?

Serge Saxonov sold 25,000 Class A common shares in five direct sales on September 22, 2026. The reported weighted-average prices were $78.2284 for 1,000 shares, $79.6195 for 2,000, $80.9033 for 9,300, $81.8254 for 9,900, and $82.3650 for 2,800.

What price ranges covered Serge Saxonov's TXG sales?

The five reported transactions were executed in multiple trades at ranges of $77.75 to $78.73, $79.11 to $80.07, $80.28 to $81.27, $81.28 to $82.25, and $82.28 to $82.53 per share. A weighted-average sale price was reported for each transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/24/2026 - 04:30 PM Accepted by SEC EDGAR 09/24/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/22/2026		S(1)		1,000	D	$78.2284(2)	1,074,249	D
Class A Common Stock	09/22/2026		S(1)		2,000	D	$79.6195(3)	1,072,249	D
Class A Common Stock	09/22/2026		S(1)		9,300	D	$80.9033(4)	1,062,949	D
Class A Common Stock	09/22/2026		S(1)		9,900	D	$81.8254(5)	1,053,049	D
Class A Common Stock	09/22/2026		S(1)		2,800	D	$82.365(6)	1,050,249	D
Class A Common Stock								27	I	See footnote(7)
Class A Common Stock								213,250	I	See footnote(8)
Class A Common Stock								71,644	I	See footnote(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

7. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

8. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

9. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)